ADDRESS: Street, City, Country
PHONE: +(123) 456 789
E-MAIL: your-email@mail.com
With this approval, AstraZeneca can market Enhertu in India for the neoadjuvant treatment of adults with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, where trastuzumab deruxtecan is followed by a taxane, trastuzumab and pertuzumab (THP).
imphoenix82
The Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Trixeo for the maintenance treatment of asthma and Enhertu, in combination with pertuzumab, for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer in the European Union (EU).
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 8447496924
HealthXploreIndia @2026. All Rights Reserved.
